Birdwatch Archive

Birdwatch Note

2023-04-08 14:05:19 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

The suspension of the drug is due to safety concerns. "The Court does not second-guess FDA’s decision-making lightly," Kacsmaryk wrote. "But here, FDA acquiesced on its legitimate safety concerns” https://www.nbcnews.com/news/us-news/abortion-pill-case-texas-judge-halts-access-mifepristone-rcna72117

Written by 315046F152AF8280D54473F7FBD31897AC05369971A0BE954A1E55C32CF81785
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1644497191971565568

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1644702968917245954
  • noteId - 1644702968917245954
  • participantId -
  • noteAuthorParticipantId - 315046F152AF8280D54473F7FBD31897AC05369971A0BE954A1E55C32CF81785 Participant Details
  • createdAtMillis - 1680962719552
  • tweetId - 1644497191971565568
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 0
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • The suspension of the drug is due to safety concerns. "The Court does not second-guess FDA’s decision-making lightly," Kacsmaryk wrote. "But here, FDA acquiesced on its legitimate safety concerns” https://www.nbcnews.com/news/us-news/abortion-pill-case-texas-judge-halts-access-mifepristone-rcna72117

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2023-04-08 14:05:19 UTC
(1680962719552)
1969-12-31 23:59:59 UTC
(-1)
2023-04-09 03:11:46 UTC
(1681009906215)
NEEDS_MORE_RATINGS 1969-12-31 23:59:59 UTC
(-1)

Note Ratings

rated at rated by
2023-04-08 18:16:13 -0500 Rating Details
2023-04-08 17:04:35 -0500 Rating Details
2023-04-08 16:24:08 -0500 Rating Details
2023-04-08 16:15:21 -0500 Rating Details
2023-04-08 16:10:33 -0500 Rating Details
2023-04-08 15:55:41 -0500 Rating Details
2023-04-08 15:27:13 -0500 Rating Details
2023-04-08 15:11:21 -0500 Rating Details
2023-04-08 13:24:49 -0500 Rating Details
2023-04-08 13:10:50 -0500 Rating Details
2023-04-08 12:51:13 -0500 Rating Details
2023-04-08 12:35:14 -0500 Rating Details
2023-04-08 12:28:47 -0500 Rating Details
2023-04-08 12:18:21 -0500 Rating Details
2023-04-08 12:15:08 -0500 Rating Details
2023-04-08 12:14:11 -0500 Rating Details
2023-04-08 12:14:02 -0500 Rating Details
2023-04-08 11:53:04 -0500 Rating Details
2023-04-08 11:51:00 -0500 Rating Details
2023-04-08 11:39:08 -0500 Rating Details
2023-04-08 11:20:17 -0500 Rating Details
2023-04-08 11:13:38 -0500 Rating Details
2023-04-08 11:05:31 -0500 Rating Details
2023-04-08 10:46:07 -0500 Rating Details
2023-04-08 10:18:43 -0500 Rating Details
2023-04-08 10:00:19 -0500 Rating Details
2023-04-08 09:57:50 -0500 Rating Details
2023-04-08 09:54:56 -0500 Rating Details
2023-04-08 09:54:27 -0500 Rating Details
2023-04-08 09:42:47 -0500 Rating Details
2023-04-08 09:27:56 -0500 Rating Details
2023-04-08 09:21:29 -0500 Rating Details
2023-04-08 09:19:23 -0500 Rating Details
2023-04-08 09:18:15 -0500 Rating Details
2023-04-08 09:16:06 -0500 Rating Details
2023-04-08 09:14:01 -0500 Rating Details
2023-04-08 09:09:01 -0500 Rating Details
2023-04-09 16:32:22 -0500 Rating Details
2023-04-09 15:01:37 -0500 Rating Details
2023-04-09 08:31:28 -0500 Rating Details
2023-04-08 21:39:03 -0500 Rating Details
2023-04-08 16:10:33 -0500 Rating Details
2023-04-08 11:05:31 -0500 Rating Details
2023-04-08 11:13:38 -0500 Rating Details
2023-04-08 16:24:08 -0500 Rating Details
2023-04-08 15:55:41 -0500 Rating Details
2023-04-08 12:18:21 -0500 Rating Details
2023-04-08 12:35:14 -0500 Rating Details
2023-04-08 15:27:13 -0500 Rating Details
2023-04-09 15:01:37 -0500 Rating Details
2023-04-08 11:51:00 -0500 Rating Details
2023-04-08 21:39:03 -0500 Rating Details
2023-04-08 13:10:50 -0500 Rating Details
2023-04-08 09:54:27 -0500 Rating Details
2023-04-08 09:54:56 -0500 Rating Details
2023-04-08 09:57:50 -0500 Rating Details
2023-04-08 18:16:13 -0500 Rating Details
2023-04-08 12:15:08 -0500 Rating Details
2023-04-08 09:16:06 -0500 Rating Details
2023-04-08 17:04:35 -0500 Rating Details
2023-04-08 09:18:15 -0500 Rating Details
2023-04-08 12:14:11 -0500 Rating Details
2023-04-08 12:51:13 -0500 Rating Details
2023-04-08 10:00:19 -0500 Rating Details
2023-04-08 11:53:04 -0500 Rating Details
2023-04-08 09:27:56 -0500 Rating Details
2023-04-09 16:32:22 -0500 Rating Details
2023-04-08 11:20:17 -0500 Rating Details
2023-04-08 16:15:21 -0500 Rating Details
2023-04-08 10:46:07 -0500 Rating Details
2023-04-08 09:14:01 -0500 Rating Details
2023-04-08 09:09:01 -0500 Rating Details
2023-04-08 12:28:47 -0500 Rating Details
2023-04-08 13:24:49 -0500 Rating Details
2023-04-08 09:21:29 -0500 Rating Details
2023-04-08 09:19:23 -0500 Rating Details
2023-04-08 15:11:21 -0500 Rating Details
2023-04-08 11:39:08 -0500 Rating Details
2023-04-09 08:31:28 -0500 Rating Details
2023-04-08 09:42:47 -0500 Rating Details
2023-04-08 10:18:43 -0500 Rating Details
2023-04-08 12:14:02 -0500 Rating Details